| 名称 | Exatecan Mesylate |
| 描述 | Exatecan Mesylate (DX8951f) is a DNA topoisomerase I inhibitor (IC50: 2.2 μM, 0.975 μg/mL). |
| 细胞实验 | Growth inhibition experiments are carried out in 96-well flat-bottomed microplates, and the amount of viable cells at the end of the incubation is determined by MTT assay. Thus, 500-20000 cells/well in 150 μL of medium are plated and grown for 24 h (P388, CCRF-CEM and K562 cells for 4h), the drug (including Exatecan Mesylate, in 150 μL medium/well), or the medium alone as a control, is added, and the cells are cultured for an additional 3 days. After the addition of MTT (20 μL/well, 5 mg/mL in phosphate-buffered saline), the plates are incubated for 4 h and centrifuged at 800 g for 5 min, then the medium is removed and the blue dye formed is dissolved in 150 μL of DMSO. the absorbance is measured at 540 nm using a Microplate Reader [1]. |
| 激酶实验 | Cells (5×10^6) are lysed with SDS buffer (10 mM HEPES, 2 mM orthovanadate, 10 mM NaF, 10 mM pyrophosphate, 1 mM PMSF, 10 μg/mL leupeptin, 10% 2-mercaptoethanol, 10% glycerol,8% SDS, 42 mM Tris-HCl, 0.002% bromophenol blue, pH 7.4). Protein in the whole-cell lysates is separated in 7.5% polyacrylamide gel and blotted onto the nitrocellulose membrane. The membrane is treated with anti-Topo I human antibody and subsequently, with horseradish peroxidase-conjugated protein A. The Topo I-specific band is detected with ECL reagents. To obtain a nuclear extract, cells (5×10^7) are washed with ice-cold buffer (2 mM K2HPO4, 5 mM MgCl2, 150 mM NaCl, 1 mM EGTA, 0.1 mM dithiothreitol), resuspended in buffer containing 0.35% Triton-X100 and PMSF and then incubated on ice for 10 min. The resulting lysates are centrifuged, and precipitates are then incubated with buffer containing 0.35 M NaCl for 1 hr at 4°C. After centrifugation (18,000g, 10 min), the protein concentration of the supernatant (nuclear extract) is determined using a protein assay kit. The same amount of nuclear protein is analyzed by Western blotting analysis using the anti-Topo I antibody [2]. |
| 动物实验 | At 3 weeks after BxPC-3-GFP and MIA-PaCa-2-GFP orthotopic implantation, mice are randomized into five different groups of 5 mice each for treatment purposes. Group 1 serves as the negative control and does not receive any treatment. Groups 2 and 3 are treated with Exatecan Mesylate at 25 and 15 mg/kg/dose, respectively. Groups 4 and 5 receive gemcitabine treatments at 300 and 150 mg/kg/dose, respectively. At 6 weeks after BxPC-3-GFP orthotopic implantation, mice are randomized into three different groups of 20 mice each for treatment purposes. Group 1 serves as the negative control and does not receive any treatment. Group 2 is treated with 25 mg/kg/dose Exatecan Mesylate and group 3 receives 300 mg/kg/dose gemcitabine. Dosing for both drugs is performed once a week for 3 weeks, discontinued for 2 weeks, and then continued for another 3 weeks. In both early and late cancer models, primary tumor size and body weights are measured once a week. Tumor volumes are calculated using the formula a × b2 × 0.5, where a and b represent the larger and smaller diameters, respectively. At the termination of the studies, mice are sacrificed and explored. Final tumor weights and direct GFP images of primary tumor and metastases are recorded for each mouse. The tumor growth IR is calculated using the formula IR (%) = (1 ? TWt/TWc) × 100, where TWt and TWc are the mean tumor weight of treated and control groups, respectively [3]. |
| 体外活性 | Exatecan Mesylate (DX-8951f) 显著抑制多种癌症细胞系的增殖，对乳腺癌细胞、结肠癌细胞、胃癌细胞和肺癌细胞的平均GI50分别为2.02 ng/mL、2.92 ng/mL、1.53 ng/mL和0.877 ng/mL [1]。Exatecan 对PC-6和PC-6/SN2-5细胞展示出细胞毒性活动，其平均GI50分别为0.186 ng/mL和0.395 ng/mL。此外，Exatecan Mesylate (34 nM) 在PC-6和PC-6/SN2-5细胞中稳定DNA-TopoI复合体 [2]。 |
| 体内活性 | Exatecan Mesylate（3.325-50 mg/kg，静脉注射）在携带肿瘤细胞的小鼠模型中展示出抗肿瘤活性，未观察到毒性死亡[1]。Exatecan Mesylate（15, 25 mg/kg，静脉注射）在MIA-PaCa-2早期模型及BxPC-3早期模型中，显著抑制MIA-PaCa和BxPC-3原发肿瘤生长。在BxPC-3晚期癌症模型中，Exatecan Mesylate（15, 25 mg/kg，静脉注射）还显著抑制了BxPC-3的淋巴转移，并完全消除了肺转移[3]。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 8 mg/mL (15.05 mM), Sonication is recommended.
H2O : 6 mg/mL (11.29 mM), Sonication and heating are recommended.
|
| 关键字 | Exatecan | Exatecan Mesylate | Topoisomerase | Inhibitor | inhibit |
| 相关产品 | Prulifloxacin | Norfloxacin | Ciprofloxacin | Berberine chloride | Etoposide | Dexamethasone acetate | Ciprofloxacin monohydrochloride | EIDD-1931 | Paclitaxel | Methotrexate |
| 相关库 | 抑制剂库 | 抗乳腺癌化合物库 | 抗癌活性化合物库 | 经典已知活性库 | 已知活性化合物库 | 抗衰老化合物库 | 抗卵巢癌化合物库 | 药物功能重定位化合物库 | 抗癌临床化合物库 | 抗癌药物库 |